Trial Profile
A Randomized Investigator and Patient Blind Placebo-controlled Parallel Group First in Human and Proof of Concept Study to Evaluate the Safety Tolerability and Efficacy of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Oct 2020
Price :
$35
*
At a glance
- Drugs CLL 442 (Primary)
- Indications Carcinoma; Squamous cell cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 29 Sep 2020 Status changed from completed to discontinued.
- 10 Dec 2018 Status changed from recruiting to completed.
- 21 Nov 2018 Planned End Date changed from 2 Nov 2018 to 16 Aug 2021.